GAP 2013 Program Sessions

General Program - April 3-5, 2013

Moon Shots:  Connect for Global Networking

Breast Cancer - Aman Buzdar
• Early detection, prevention, treatment, local therapies, systemic therapies (either related to early  or advanced disease)
• Any aspect of these approaches that are being evaluating at your institution and are unique in the global context

Biobanking Across the Sister Institution Network - Tyron Hoover/Mary Edgerton
The biobanking session will provide information of interest to both existing banks and those institutions interested in starting banks. The session will address the practical aspects of collecting, storing, and annotating human biospecimens for cancer research from both the point of view of harmonizing procedures and data collection across existing banks and establishing new banks across the sister institution network. Topics will include, but not necessarily be limited to, operations, management, personnel, regulatory oversight, quality control, ethics, protocol generation, informed consent processes, inventory management, tissue informatics, and the creation of a framework for promoting tissue and data sharing and collaborative research.  Case studies from MD Anderson will be presented to illustrate these aspects, and we invite submissions from other institutions to present approaches to problem solving in these areas. Additionally, though not part of the formal program, a “show-and-tell” tour of MD Anderson’s biobank(s) with a demonstration of our inventory management software system will be offered informally to attendees.

Cancer Control Platform (plenary and workshop) - Ernest Hawk/Mark Moreno
Cancer control seeks to reduce the population’s burden of cancer by the systematic collection and analysis of data on cancer-related behaviors, preventive/screening practices, and cancer outcomes (e.g., incidence, mortality, survival) across time considering important demographic subsets, and the implementation of public health strategies designed to address them. Typical public health strategies involve development, implementation, and dissemination of public policies, educational programs targeting the public or health professionals, and preventive/screening services tailored to the specific needs of the population. As with clinical services, cancer control programs strive to achieve their goals while optimizing programmatic effectiveness, efficiency, timeliness, safety, and equity to address the most important needs of the population, while minimizing important disparities in cancer-related health practices, preventive/screening services, programmatic outreach, and outcomes. In this session, we will review a variety of successful programs employed by our global partners – from the stages of programmatic planning and design, through implementation, dissemination and evaluation – that are achieving measureable results toward the goal of reducing their community’s cancer burden.

Delivering High Value Cancer Care:  Meeting the Challenge of Doing More with Less
Thomas W. Feeley
Throughout the world, economies are struggling to deal with increasing costs of health care while maintaining the quality of care. At MD Anderson, our Institute for Cancer Care Excellence has been developing strategies to provide value-based cancer care:  the best outcomes at the most reasonable costs.  This session will provide an overview the programs we are developing to better understand, improve and report outcome measures that matter to our patients and to better understand and control the costs of the care we deliver.  We hope to hear from selected programs about the innovative work you are doing to optimize the value of the care you provide to your cancer patients.  Abstracts should include a brief description of your health care system and innovative programs that address one or both aspects of value-based care:  improving outcomes and controlling costs.  We hope that this open exchange of information will be beneficial to you, your institution, and most importantly, the patients you care for.

Diagnostic Imaging (workshop) – Erik Paulson
• Novel and innovative imaging applications
• Novel and innovative interventional applications
• CT dose reduction
• Screening for malignancy
• Economic aspects of imaging
• Process improvement in imaging

Early Detection Workshop - Samir Hanash
With the demonstrated success in reducing lung cancer mortality through low dose CT, there is a need to implement early detection programs through imaging, to be complemented with biomarkers to reduce false positives. Opportunities to develop such programs at MD Anderson and at partner institutions will be presented and discussed in this session.

Genomic Medicine I (pre-clinical) - Andrew Futreal/Gulio Draetta
• Technology and computation
• Identification of targets
• Targeted new therapies
• Institute for Applied Cancer Science (IACS)

Genomic Medicine II (clinical) – John Mendelsohn/Gordon Mills/Funda Meric-Bernstam
• Clinical decision support
• Biomarkers
• Trials with experimental targeted therapies
• Clinical infrastructure
• Institute for Personalized Cancer Therapy (IPCT) 

Gynecology - Lois Ramondetta
• Cervical cancer prevention projects in low resource settings
• Cervical cancer – identifying patients requiring more than standard therapy
• Palliative Care for Gynecologic Cancers
• Ovarian cancer interventions with high impact on mortality (prevention and early detection, novel therapies)
• Obesity science and gynecologic cancers

Head and Neck - Jeff Myers
• Symptom burden of head and neck cancer treatment
• HPV related head and neck cancer – global perspectives

Infectious Diseases in Cancer - Isaam Raad / Javier Adachi
Worldwide, infectious problems are associated with significant morbidity and mortality in the immunocompromised cancer patients. The objective of this session is to provide a didactic setting to share our knowledge and compare the differences in epidemiology, early diagnosis, novel therapy, prevention and management of bacterial, fungal and viral infections in cancer patients; in close interaction with the specific social and environmental characteristics of each of our Countries. Moreover, this session will aim to foster future collaborative research projects between MDACC and our Sister Institutions around the world.  We will have one “state-of-the-art” conference followed by oral presentations of scientific abstracts.

Integrative Medicine - Richard Tsong Lee
• Clinical models of Integrative Oncology
• Incorporating  Clinical Outcomes and Research in the Clinic
• Practical Aspects of Starting an Integrative Oncology Program

Moon Shot - Acute myeloid leukemia and myelodysplastic syndrome (AML/MDS)
Guillermo Garcia-Manero, M.D., Professor, Leukemia
Hagop Kantarjian, M.D., Chair and professor, Leukemia
Myelodysplastic syndromes, or MDS, are a group of malignancies affecting blood cells. About half of MDS patients go on to develop acute myeloid leukemia (AML), which is the most common leukemia in adults. Together, these diseases affect nearly 16,000 Americans each year.  The incidence of MDS is expected to rise as the population ages. There’s no curative therapy for most patients with MDS. Although the five-year survival rate for AML has vastly improved since the 1970s, it’s still only less than 30%. In addition, half of AML and MDS patients will succumb to complications from their disease or treatment. Clearly, now is the time to find more effective therapies for both of these diseases.  MD Anderson’s AML/MDS moon shot will combine the latest treatment technologies and genetic knowledge to identify the most promising new treatments and move them into a clinical setting in a faster, more efficient way.

Moon Shot - Chronic lymphocytic leukemia (CLL)
Michael Keating, M.D., Professor, Leukemia
William Plunkett, Ph.D., Professor, Experimental Therapeutics
The purpose of the CLL Moon Shot program, in keeping with the overall Moon Shot concept, is to dramatically change the outcome of patients with CLL. Many aspects of research will be intertwined; (a) the genetic profile of the CLL cells, (b) the microenvironment which sustains the malignant cells, (c) the development of new agents which are safer and less damaging to DNA and the immune environment, and (d) concepts of delivering targeted, autologous T- lymphocytes to the CLL cells are all being integrated into a clinical program to improve survival. CLL is an excellent example of the progression of a malignant process from the very early stages (monoclonal B cell lymphocytosis) to indolent cases with progressive disease and those that transform into a usually fatal large cell transformation.  A number of agents which are very effective in CLL and move away from traditional cytotoxic chemotherapy are now available for study. Agents which inhibit the B cell receptor pathway such as ibrutinib and GS-1101 are being complemented by agents that trigger apoptosis such as ABT-199, and lenalidomide which enhances the immune therapy and can be combined with monoclonal antibodies to improve survival particularly of older patients with CLL. The development of chimeric antigen receptors (CARs) will enable us to deliver cytotoxic autologous T lymphocytes to target a protein ROR1 which comes from the ROR1 gene which is present almost exclusively in CLL cells. The purpose in shifting to non-cytotoxic chemotherapy regimens is the high incidence of second cancers which occur in CLL, particularly those that start on treatment with cytotoxic drugs. The genomics, proteomics, immunology, and big data analytics platforms of the Moon Shot will enable this integrated CLL program to double the ten-year survival fraction from 35% to 70-75% within the next five years.

Moon Shot - Lung cancer
John Heymach, M.D., Ph.D., Associate Professor, Thoracic/Head and Neck Medical Oncology
Stephen Swisher, M.D., Chair and Professor, Thoracic and Cardiovascular Surgery
The lung cancer moon shot will accelerate gains and discover new ways to improve survival with a massive mobilization of institutional expertise in lung cancer risk assessment, smoking prevention and cessation, spiral CT screening, development of targeted therapies and the molecular profiling of tumors necessary for a more individualized approach.  The lung cancer moon shot has three major initiatives:
• Integrated Smoking Prevention, Risk and Early Detection (INSPiRED) initiative.  INSPiRED will include proven programs in tobacco prevention outreach to youth and smoking cessation developed in the Division of Cancer Prevention and Population Sciences. Molecular and clinical risk assessment models will help identify past and present smokers most appropriate for spiral CT screening.
• BATTLE Therapeutics Program takes MD Anderson’s approach of matching cancer drugs to specific mutations in tumors developed in its BATTLE clinical trial for late-stage lung cancer and extends it to early stage and locally advanced lung cancer.  
• Target and Drug Discovery Program will collaborate with MD Anderson’s Institute for Applied Cancer Science to establish preclinical and drug-screening platforms that will identify molecular targets and develop drugs to hit them. This will include screening of existing FDA-approved drugs for other diseases during the moon shot’s early years.

Moon Shot - Melanoma
Jeffrey Gershenwald, M.D., Professor, Surgical Oncology
Michael Davies, M.D., Ph.D., Assistant Professor, Melanoma Medical Oncology
The Melanoma Moon Shot proposes several initiatives with the shared goal to make significant impact on the incidence, morbidity, and mortality due to this aggressive disease.  This program aims to undertake efforts in prevention, risk stratification, biomarkers, and therapeutic development.  We invite interested investigators to meet to discuss these efforts, and to identify opportunities for collaboration.

Moon Shot - Prostate cancer
Christopher Logothetis, M.D., Chair and Professor, Genitourinary Medical Oncology
Timothy Thompson, Ph.D., Professor, Genitourinary Medical Oncology – Research
• Distinguishing clinically significant localized prostate cancer from “clinically insignificant” cancers
• Application of marker-driven therapies to optimize efficacy according to state of progression
• Optimal targeting of oncogenetic pathways and development of novel therapeutic approaches to castrate-resistant prostate cancer

Moon Shot - Women’s cancers: triple negative breast and ovarian
Gordon Mills, M.D., Ph.D., Chair and Professor, Systems Biology
Mien-Chie Hung, Ph.D., Chair and Professor, Molecular and Cellular Oncology
Anil Sood, M.D., Professor, Gynecologic Oncology and Reproductive Medicine
• Development, refinement and implementation of approaches to tailor surgical intervention
• Molecular marker-driven treatment of recurrent/metastatic disease
• Universal genetic testing, outreach, and family based counseling and prevention
• Early detection
• Novel consolidation treatment paradigms
• Rational combinatorial therapy
• Improved quality of life
• Innovative biomarker-driven clinical trials

Nanomedicine In Cancer Bulent Ozpolat/Gabriel Lopez-Berestein
Nanotechnology is considered as an emerging technology that has the potential to revolutionize cancer therapy, imaging and diagnosis. At the National Institutes of Health (NIH), nanomedicine is one of the priority areas under its Roadmap Initiatives. Due to major advances in science and engineering, nanotechnology applications has been expanding significantly in variety of areas in Medicine. Presentations may include on all areas of Nanomedicine regarding nano-delivery systems, Drug delivery, Imaging, Diagnosis, Nanomedicine in theranostics, novel synthetic approaches in Nanomedicine, and toxicology aspects in Nanomedicine.

Renal/Kidney – Surena Matin
• Role of multimodality management in kidney cancer
• Robotic surgery for partial nephrectomy
• Role of environmental toxins in UTUC

Smoking Cessation - Paul Cinciripini
• Review of the basic neurobiology of addiction and epidemiology of nicotine dependence
• Review of smoking cessation guideline based treatment recommendations and recent advances in pharmacological intervention for nicotine dependence
• Design and outcome of a comprehensive smoking cessation program for cancer patients

Survivorship - Lewis Foxhall
With a goal of maximizing duration of survivorship along with quality of life, delivery of preventive services to survivors is critically important.  The report of the Institute of Medicine, Cancer Survivors Lost in Transition, highlights the gap in delivery of primary and secondary preventive interventions for individuals who have completed treatment from cancer.  Primary prevention including smoking cessation, promotion of appropriate physical activity and nutrition as well as immunizations may be neglected in this population.  Second, primary cancers are a significant risk for many cancer survivors yet delivery of evidence based screening is often not offered in accordance with guidelines.  Further, tertiary prevention, including interventions to alleviate persistent or late occurring symptoms related to cancer treatment not be delivered in a timely fashion to minimize adverse effects.  

Upper GI Malignancies - Milind Javle
Upper gastrointestinal cancers represent a significant cancer burden across the globe and typically require multi-disciplinary management. The objectives of this session are to discuss important advances in research, prevention and therapies for gastric, esophageal, pancreatic and hepatobiliary cancers. We aim to encourage dialogue among health care providers, researchers and other members of the GI cancer community. We will have two high-impact “state-of-the-art” reviews followed by scientific abstract presentations.

New:  Sister Institution Multicenter Trials (not for abstract submission)
• Processes and Policies
• Clinical Research Regulations
• Research Training & Education
• Quality Assurance & Quality Control
• Clinical Research Support Services